SRPT is up another 15 percent today - and trading considerably higher than it was before the 'Bad news.' The story I've heard is that the FDA is under a lot of pressure to do something positive for Muscular Dystrophy patients and might approve the drug despite the negative vote by the FDA panel.
The cost / benefit ratio is favorable. In other words, if they reject eteplirsen, the stock could fall by $16. If they approve eteplirsen, the stock shoots to $100. That makes it worth buying for those who think the odds of approval are better than one in six.
Gold is $1,581/oz today. When it hits $2,000, it will be up 26.5%. Let's see how long that takes. - De 3/11/2013 - ANSWER: 7 Years, 5 Months |